Silencing Apoe with divalent‐siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease

• DOI: 10.1002/alz.13703
• Publication Date: 2024-02-20T11:26:14Z
• Authors: Chantal M. Ferguson; Samuel Hildebrand; Bruno M. D. C. Go...; Julianna Buchwald; Dimas Echeverria; Andrew Coles; Anastasia Grigorenko; Lorenc Vangjeli; Jacquelyn Sousa; Nicholas McHugh; Matthew Hassler; Francesco Santarelli; Michael T. Heneka; Evgeny Rogaev; Anastasia Khvorova
• Keywords: 0301 basic medicine; Amyloid; Amyloid beta-Peptides; Apolipoprotein E4; neurodegeneration; oligonucleotide therapeutics; Brain; Amyloidogenic Proteins; Mice, Transgenic; Alzheimer's Disease; Mice; 03 medical and health sciences; Apolipoproteins E; Alzheimer Disease; RNAi; siRNA; Animals; RNA, Small Interfering; Research Articles; Apoe

AbstractINTRODUCTIONThe most significant genetic risk factor for late‐onset Alzheimer's disease (AD) is APOE4, with evidence for gain‐ and loss‐of‐function mechanisms. A clinical need remains for therapeutically relevant tools that potently modulate APOE expression.METHODSWe optimized small interfering RNAs (di‐siRNA, GalNAc) to potently silence brain or liver Apoe and evaluated the impact of each pool of Apoe on pathology.RESULTSIn adult 5xFAD mice, siRNAs targeting CNS Apoe efficiently silenced Apoe expression and reduced amyloid burden without affecting systemic cholesterol, confirming that potent silencing of brain Apoe is sufficient to slow disease progression. Mechanistically, silencing Apoe reduced APOE‐rich amyloid cores and activated immune system responses.DISCUSSIONThese results establish siRNA‐based modulation of Apoe as a viable therapeutic approach, highlight immune activation as a key pathway affected by Apoe modulation, and provide the technology to further evaluate the impact of APOE silencing on neurodegeneration.